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Zusammenfassung
Hintergrund: Die Studie analysiert, inwieweit der Body-Mass-
Index (BMI) Einfluss auf prognostisch relevante klinische 
und pathologische Mammakarzinom-Merkmale in einem 
Land hat, in dem die global zu beobachtende «obesity epi-
demic» bisher ausgeblieben ist. Patienten und Methoden: 
Aus den Daten der Mammakarzinom-Datenbank der Basler 
Universitäts-Frauenklinik, welche einen 20-Jahres-Zeitraum 
dokumentiert (1990–2009, 1459 Patientinnen), wurde der 
Einfluss des BMI auf folgende prognostisch relevante Varia-
blen untersucht: Tumorgröße und -stadium, histologischer 
Subtyp, Grading, Hormonrezeptorstatus, HER2-Status, 
«triple-negativer»-Status. Das multivariate Berechnungsmo-
dell berücksichtigte neben dem BMI das Alter der Patientin. 
Ergebnisse: Die Korrelationen zwischen steigendem BMI 
und den oben genannten Faktoren waren wie folgt (Angaben 
jeweils: Odds ratio (OR), 95% Konfidenzintervall, p-Wert): 
Tumorgröße, a) alle Patientinnen: 0,03 (0,01–0,05), p < 0,001, 
b) Tumor von Patientin selbst bemerkt/getastet: 0,05 (0,03–
0,07), p < 0,001, c) Tumor durch bildgebende Verfahren ent-
deckt: 0,03 (0–0,07), p = 0,044; höheres TNM-Stadium: 1,16 
(1,02–1,31), p = 0,022; histologischer Subtyp: 1,04 (0,89–1,22), 
p = 0,602; ungünstiges Grading: 1,11 (1,00–1,25), p = 0,057; 
positiver Östrogenrezeptorstatus: 0,95 (0,83–1,09), p = 0,459; 
positiver HER2-Status: 0,92 (0,74–1,15), p = 0,467; Vorliegen 
eines «triple-negativen» Karzinoms: 1,19 (0,93–1,52), p = 
0,165. Nur postmenopausale Patientinnen berücksichtigend 
(n = 1063), änderten sich die Ergebnisse nur marginal. 
Schlussfolgerungen: Mit steigendem BMI wurde eine posi-
tive Korrelation zu einem höheren TNM-Stadium, einem un-
günstigen Grading und der Tumorgröße (sowohl für die 
Fälle, bei denen der Tumor von den Patientinnen selbst 
 bemerkt/getastet wurde, als auch für die Tumoren, die mit 
radiologischen Verfahren detektiert wurden) gefunden. 
Keywords
Breast cancer · Body mass index · Tumor size ·  
Prognostic factors · Tumor detection
Summary
Background: This study analyzes the association of body 
mass index (BMI) and prognostically relevant breast cancer 
(BC) characteristics in a country that has been rather spared 
of the global obesity epidemic. Patients and Methods: 
Based on 20-year data (1999–2009, n = 1,414) of the pro-
spective relational BC database of the University Hospital 
Basel, Switzerland, the associations between BMI, tumor 
size and stage, histological subtype, grading, hormonal re-
ceptor status, HER2 status and ‘triple-negative’ status were 
evaluated. Multivariate analysis considered BMI and pa-
tient’s age. Results: The association between increasing 
BMI and the above-mentioned variables were as follows (re-
sults described in each case: Beta-coefficient or odds ratio, 
95% confidence interval, p value): tumor size, (1) entire 
 cohort: 0.03 (0.01–0.05), p < 0.001, (2) tumor found by self-
palpation: 0.05 (0.03–0.07), p < 0.001, (3) tumor found by 
 radiological examination: 0.03 (0–0.07), p = 0.044; advanced 
TNM stage: 1.16 (1.02–1.31), p = 0.022; histological subtype: 
1.04 (0.89–1.22), p = 0.602; unfavorable grading: 1.11 (1.00–
1.25), p = 0.057; positive estrogen receptor status: 0.95 
(0.83–1.09), p = 0.459; positive HER2 status: 0.92 (0.74–1.15), 
p = 0.467; presence of a ‘triple-negative’ carcinoma: 1.19 
(0.93–1.52), p = 0.165. Consideration of only postmenopau-
sal BC patients (n = 1,063) did attenuate the results, but did 
not change the direction of the associations with BMI. Con-
clusion: BMI was positively associated with TNM stage, 
grading and tumor size for tumors that were found by self-
detection, as well as for those lesions detected by radiologi-
cal breast examinations.
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Introduction
In most epidemiological studies, obesity is associated with an 
increased risk of postmenopausal breast cancer (BC), while 
an inverse relationship is observed in premenopausal women. 
In addition, being obese has been shown to influence BC 
prognosis adversely [1–3]. It has been suggested that larger 
tumor size, more advanced stage and grade of the tumor at 
diagnosis [4] could explain in part this bad outcome. The find-
ings of several studies are in accordance with this hypothesis 
[5, 6]; however, others are not [7].
Unfavorable tumor characteristics may also explain the 
worse outcome of obese BC patients [2]. Furthermore, histo-
logical BC subtypes may differ in their associations with 
 established BC risk factors [8–11]. The few studies exploring 
the association between body size and aggressive triple-nega-
tive BC (TNBC) reported largely inconsistent results [12]. On 
the other hand, evidence of a positive association between 
body size and estrogen receptor (ER)-positive BC is quite 
consistent [13–15]. For example, Phipps et al. [12] in their 
 cohort study including 155,723 women enrolled in the 
 Women’s Health Initiative found an increased risk of TNBC 
(odds ratio (OR) = 1.35; 95% confidence interval (CI): 
0.92–1.99) and ER-positive carcinomas (OR = 1.39; 95% CI: 
1.22–1.58) for women in the highest, compared with the 
 lowest, body mass index (BMI) quartile. Even though the ER-
positive BC subtype has a rather good prognosis, obesity in 
postmenopausal women may result in more biologically 
 aggressive ER-positive tumors [16, 17]. 
To evaluate some of these controversial issues, we used 
data from a Swiss prospective BC database. Data from Swit-
zerland is particularly interesting since the prevalence of over-
weight and obesity are low when compared to international 
statistics, and it seems, so far, that Switzerland, similar to a 
few other countries such as Italy or Sweden, has been spared 
from the globally observed ‘obesity epidemic’ [18–20]. For the 
present analysis, we evaluated the impact of BMI and age on 
the following prognostically relevant factors: tumor size (tumor 
detected by self-palpation or by radiological examination) 
and stage, histological subtype, grading, hormonal receptor 
status, HER2 status, ‘triple-negative’ status (hormonal recep-
tor and HER2 status negative) and the risk score defined at 
the St. Gallen Expert Consensus Meeting in 2007 [21].
Patients and Methods
Based on the prospective relational web-based Basel Breast Cancer 
 Database (BBCD) of the University Women’s Hospital Basel (Basel, 
Switzerland), which documents all newly diagnosed and treated invasive 
breast carcinomas at this institution over a 20-year period (1990–2009, 
1,459 patients), we evaluated the impact of BMI on prognostically rele-
vant tumor characteristics of BC patients. 
The predictor variable of our study was BMI. This variable was calcu-
lated using the following standard formula: body weight (kg)/height (m2). 
In this study, we exclusively used directly measured BMI data taken at 
the time of initial BC diagnosis. No BMI information was available for 
only 44 women of the entire BBCD cohort; thus, our study cohort com-
prised 1,415 patients. Besides age at initial diagnosis, the following clin-
icopathological features/characteristics were evaluated: tumor cate gories 
and stage according to the current American Joint Committee on Cancer 
(AJCC)/International Union Against Cancer (UICC) TNM classification 
[22, 23]; histological subtype; grading; hormonal receptor status (ER 
 status and progesterone receptor (PR) status); HER2 status (HER2 has 
routinely been assessed for all patients since 2002 (n = 665) and was avail-
able for 660 patients (46.6% of the entire study cohort)); TNBC; and risk 
score (as defined at the St. Gallen Expert Consensus Meeting in 2007) 
[21].
In addition, we considered the method of tumor detection, and 
 evaluated 3 different methods: self-detection, clinical breast examination 
and radiological breast examination including mammography and 
sonography.
Table 1. Basel Breast Cancer Database 1990–2009: clinicopathological 
characteristics of 1415 patients
Characteristic
Age at diagnosis, median in years (range)   61 (26–95)
BMI median (range)   24.7 (14.3–53.3)
< 18.5, n (%)   38 (2.7)
18.5–24.9, n (%)  712 (50.3)
25–29.9, n (%)  425 (30.0)
≥ 30, n (%)  240 (17.0)
Tumor size, median in mm (range)   20 (0–220)
T1, n (%)  717 (50.7)
T2, n (%)  523 (37.0)
T3, n (%)   80 (5.7)
Non-inflammatory T4, n (%)   70 (5.0)
Inflammatory carcinoma  
(no tumor size recorded), n (%)
  23 (1.6)
Missing, n    2
TNM stage, n (%)
I  527 (37.2)
II  558 (39.5)
III  249 (17.6)
IV   81 (5.7)
Histological subtype, n (%)
Ductal invasive 1097 (78.4)
Lobular invasive  197 (14.1)
Other types  106 (7.5)
Missing, n   15
Grading, n (%)
G1/G2  786 (57.6)
G3  578 (42.4)
Missing, n   51
Hormone receptor status, n (%)
ER positive /PR positive  867 (64.1)
ER negative / PR negative  239 (17.7)
Missing (n)   63 
HER2 receptor status (2002–2009)
Known, n  660
Positive, n (%)  113 (17.1)
‘Triple negativity’ (2002–2009)
ER/PR/HER2 known, n  660
Positive, n (%)  70 (10.6)
St. Gallen risk score (2002–2009)
Known ER/PR/HER2 statusa, n  579 
Low, n (%)   82 (14.2)
Intermediate, n (%)  400 (69.1)
High, n (%)   97 (16.7)
BMI = body mass index, ER = estrogen receptor,  
PR = progesterone receptor.
a Only applicable for patients who had primary surgery  
(i.e. pTNM classification).
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Statistical Analysis
To evaluate the impact of BMI and age on tumor characteristics (tumor 
size and stage, histological subtype, grading, hormonal receptor status, 
HER2 status, ‘triple-negative’ status and the St. Gallen risk score) we 
 created multivariate models (linear or logistic regression) including BMI 
and patient’s age at diagnosis for (1) the entire cohort (n = 1,415), and (2) 
for postmenopausal women only (n = 1,063). Results of linear regression 
models are reported as beta-coefficients and corresponding 95% CIs; 
 results of logistic regression models are reported as ORs with correspond-
ing 95% CIs. Statistical analyses were performed with R Development 
Core Team software, version 2.5.0 (Vienna, Austria). 
Data collection methods and study design were approved by the Insti-
tutional Ethical Review Board.
Results
Of the 1,415 BC patients included in the present study, 50.3% 
had normal body weight (BMI 18.5–< 25 kg/m2), 30.0% were 
overweight (BMI 25–< 30 kg/m2) and 17.0% obese (BMI 
≥ 30 kg/m2); the median age was 61 years (range: 26–95). Clin-
icopathological features of this cohort of patients are summa-
rized in table 1.
Table 2 shows the associations between tumor charac-
teristics, BMI and age. The multivariate analyses in-
cluded the  directly measured BMI (as a continuous vari-
able) and patient’s age, each at the time of the initial 
cancer diagnosis. 
With regard to the impact of age on tumor characteristics, 
the present study revealed a positive association between 
 advancing age and the probability of being diagnosed with 
lobular instead of ductal BC (OR = 1.18; 95% CI = 1.06–1.32, 
p = 0.003). Furthermore, increasing age was associated with 
a more favorable grading (OR = 0.91; 95% CI = 0.84–0.98, 
p = 0.019) and a higher probability of a positive ER status 
(OR = 1.23; 95% CI = 1.11–1.35, p < 0.001). With increasing 
age, TNBC were diagnosed less often (OR = 0.71; 95% CI = 
0.59–0.86). No associations were observed between advancing 
age and tumor size (independent of detection modus), TNM 
and HER2 status, and St. Gallen risk score.
Table 2. Association of BMI and age with prognostic relevant breast cancer characteristics
Entire cohort p valuea Postmenopausal women p valuea
Beta-coefficient (95% CI)
Tumor size (all patients)
BMIb
Agec
0.03 (0.01–0.05)
0.01 (0–0.02)
< 0.001
0.082
0.03 (0.01–0.05)
0.01 (0.02–0.05)
0.002
< 0.001
Tumor size (tumor detected by self-examination)
BMIb
Agec
0.05 (0.03–0.07)
0.001 (0–0.02)
< 0.001
0.188
0.04 (0.02–0.06)
0.01 (-0.01–0.03)
< 0.001
0.349
Tumor size (tumor detected by mammography or sonography)
BMIb
Agec
0.03 (0–0.07)
0 (-0.03–0.03)
0.044
0.840
0.03 (0.0–0.07)
0.02 (-0.03–0.06)
0.076
0.457
OR (95% CI)
TNM stage (III/IV vs. I/II)
BMIb
Agec
1.16 (1.02–1.31)
0.97 (0.89–1.06
0.022
0.525
1.06 (0.92–1.23)
1.01 (0.88–1.17)
0.402
0.833
Histological subtype (lobular vs. ductal)
BMIb
Agec
1.04 (0.89–1.22)
1.18 (1.06–1.32)
0.602
0.003
1.05 (0.89–1.25)
1.09 (0.92–1.28)
0.573
0.324
Grading (3 vs. 1 and 2)
BMIb
Agec
1.11 (1.00–1.25)
0.91 (0.84–0.98)
0.057
0.019
1.10 (0.97–1.2)
0.91 (0.81–1.03)
0.135
0.151
ER status (positive vs. negative)
BMIb
Agec
0.95 (0.83–1.09)
1.23 (1.11–1.35)
0.459
< 0.001
0.99 (0.84–1.16)
1.20 (1.02–1.40)
0.874
0.025
HER2 status
(2002–2009: positive vs. negative)
BMIb
Agec
0.92 (0.74–1.15)
0.95 (0.82–1.10)
0.467
0.495
0.92 (0.72–1.18)
0.97 (0.77–1.22)
0.526
0.786
‘Triple negativity’ (2002–2009: yes vs. no)
BMIb
Agec
1.19 (0.93–1.52)
0.71 (0.59–0.86)
0.165
< 0.001
0.87 (0.64–1.17)
1.35 (0.99–1.84)
0.350
0.052
St. Gallen risk score (2002–2009: high vs. low)
BMIb
Agec
1.24 (1.00–1.55)
0.88 (0.75–1.02)
0.049
0.091
1.20 (0.94–1.53)
0.89 (0.70–1.12)
0.154
0.308
BMI = body mass index, CI = confidence interval, OR = odds ratio, ER = estrogen receptor. 
a p value: statistically significant: < 0.05.
b per 5 BMI units. c per 10 years.
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Regarding the impact of BMI on tumor characteristics, 
i ncreasing BMI was associated with increasing tumor size in 
the entire cohort, such that the tumor increased by 3 mm per 
5 unit change in BMI (beta-coefficient 0.03; 95% CI = 0.01–
0.05, p < 0.001) and in patients who found the tumor by self-
palpation (beta-coefficient = 0.05; 95% CI = 0.03–0.07, 
p < 0.001) as well as in women in whom the cancer was  detected 
by radiological examination (mammography or sonography) 
(beta-coefficient = 0.03; 95% CI = 0–0.07, p = 0.044).
Increasing BMI was also related to more advanced TNM 
stage at diagnosis (OR = 1.16; 95% CI = 1.02–1.31, p = 0.022), 
unfavorable grading (OR = 1.11; 95% CI = 1.00–1.25, p = 
0.057) and a higher St. Gallen risk score (OR = 1.24; 95% CI 
= 1.00–1.55, p = 0.049). No significant associations were 
 observed between BMI and histological subtype (lobular vs. 
ductal), positive ER status, positive HER2 status, and the 
presence of a TNBC.
Limiting the group of women to postmenopausal BC pa-
tients attenuated the results mentioned above, but did not 
change the direction of the correlations/associations (see 
table 2) with the exception of triple negativity and age.
Discussion
There is increasing evidence that BMI is inversely associated 
with BC prognosis [1, 7, 17]. However, at present, the causal 
mechanisms are still under investigation. This may partly be 
due to a poor compliance to BC screening. Compliance and 
persistence with medical measures are strongly determined by 
personal motivations, which are determined by a considerable 
number of individual psychosocial and medical factors. Few 
published studies have evaluated the impact of body weight 
on compliance and persistence with BC therapy [2, 24–26]. 
However, the complex relationship between BMI and accept-
ance of medical measures has been rather well examined with 
regards to mammography screening rates. Some authors re-
ported significantly lower compliance with BC screening in 
obese women [27–29], although others did not confirm this 
finding in a large population-based analysis of more than 
130,000 women [30]. The reasons why a significant number of 
obese patients delay or refuse to participate in cancer screen-
ing programs are not yet fully understood. One of the most 
common reasons women give is the embarrassment of being 
weighed or having to undergo a physical exam with even more 
embarrassing aspects to endure (e.g. too small gowns, exami-
nation tables, instruments) [28, 29, 31]. A further crucial point 
is the physician’s attitude towards obese patients. The litera-
ture reports a considerable amount of negative and stereotyp-
ical attitudes toward obese patients that can be interpreted as 
decreased respect for obese patients [29, 32, 33]. This attitude 
is clearly felt by the patients, influencing them in their behav-
ior and decisions [32–34].  Efforts are needed to avoid these 
deterrents.
The worse outcome in obese women could also be due to 
more advanced stage at diagnosis and/or the difficulty in 
 palpating these tumors. Additionally, obese BC patients may 
have more aggressive cancers [17]. Obesity is accompanied 
with the up-regulation of various cellular proliferation path-
ways [35]. Adipokines and estrogens, produced in adipose 
 tissue, may enhance tumor cell proliferation and metastasis 
[35–37], and may potentially result in more aggressive ER-
positive cancers in postmenopausal women [16].
In the present study, BMI was significantly associated with 
tumor size. This applied not only to the cases in which the 
tumor was found by self-detection, but also to lesions detected 
by radiological breast examinations. In addition, a higher 
BMI was positively correlated with advanced TNM stage, 
 unfavorable grading, and a higher St. Gallen risk score. No 
associations were observed between BMI and histological 
subtype, ER status, HER2 status and TNBC. Higher age, on 
the other hand, increased the probability of lobular instead of 
ductal BC, less TNBC, ER positivity and more favorable 
grading. In the subgroup of postmenopausal women, the 
above-mentioned findings were attenuated but did not change 
the direction of the associations.
Age and Prognostically Relevant Tumor Characteristics 
BC in elderly women seems to be of a less aggressive nature 
than in younger patients [38]. Our observed associations with 
age are in accordance with the findings in the literature for 
Caucasian women [39]. At a higher age, tumors are more 
often ER positive [39–42]. In the study by Parise et al. [39], 
the increase in the percentage of the ER+/PR+/HER2– subtype 
with increasing age almost mirrored the increasing proportion 
of BC cases in white women [39]. This BC subtype has the 
best overall 5-year relative cumulative survival [40]. On the 
other hand, the triple negative subtypes are found more often 
in younger than in older women [39, 40, 43–45].
BMI and Breast Cancer: Tumor Size, TNM stage,  
Grading, and St. Gallen Risk Score
Although in several reports obesity was positively associated 
with advanced stage, increased tumor size and unfavorable 
grading of breast carcinomas at diagnosis, these findings were 
not confirmed in other surveys [7]. Accordingly, Wasserman 
et al. [46] observed no association between BMI and disease 
stage at diagnosis in 301 postmenopausal women of the 
 Women’s Healthy Eating and Living study. The same was 
true for women of any age in another study [47]. Similarly, in 
the study by Chagpar et al. [7], no association was observed 
between BMI and tumor size, lymph node status, or disease 
stage at diagnosis in mostly postmenopausal women with 
 hormonally sensitive BC. In contrast, several other studies 
 observed a positive association between BMI and disease 
stage, tumor size and lymph node status at diagnosis [5, 6, 48], 
as we did in our survey for tumor size and stage. In a study 
carried out in the canton of Geneva, Switzerland [2], invasive 
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carcinomas larger than 1 cm were more frequently impalpable 
in obese women (22%) than in normal/underweight women 
(12%). It may be more difficult for clinicians and women to 
palpate a tumor in a large breast than in a small one. Thus, 
obese women with larger breasts may have larger tumors and 
more advanced tumor stages at diagnosis than lean women 
with small breasts. Accordingly, in a study of 2,863 patients 
diagnosed with BC in Wisconsin, elevated BMI was associ-
ated with a greater probability of nonlocalized tumors in self-
detected cancers, but in women whose tumors were found by 
screening mammography or by clinical breast examination, 
BMI was not related to disease stage [49]. In the present 
study, however, BMI was found to be a significant factor for 
tumors found by self-detection, as well as for those detected 
by radiological breast examinations. Thus, either both meth-
ods for tumor detection are impaired by large breasts, or 
larger tumors in larger breasts could be the consequence of 
obesity. In this context, the results of an Australian study [50] 
on the outcome of mammography in women with large 
breasts is of interest: the sensitivity and specificity of mam-
mography were greater in women with larger breasts than in 
other women.
Non-adherence to BC screening is another possible expla-
nation for our findings. Obese women are less likely to follow 
physician’s recommendations for breast and cervical cancer 
screening [29]. On the basis of 10 studies, among women in 
the U.S., Cohen et al. found that obesity most likely is a bar-
rier to screening for BC, particularly among white women 
[51], although this is not universally so [52]. In the present 
study, we could not comment on this explanation because 
until now only opportunistic screening exists in the Basel 
region.
BMI and Breast Cancer: ER status, HER2 status and TNBC 
Obesity may affect BC risk by increasing circulating endoge-
nous estrogen levels [53]. Thus, the association between body 
weight and BC risk may be modified by the tumor’s ER and 
PR status. The summarized findings of 9 cohort and 22 case-
control studies comparing the highest versus the reference 
categories of relative body weight observed that the risk for 
ER+PR+ tumors was 20% lower (95% CI = -30 to -8%) among 
premenopausal and 82% higher (95% CI = 55–114%) among 
postmenopausal women [15]. No associations were observed 
for ER–PR– or ER+PR– tumors. More recent studies con-
firmed these findings [2, 12, 54, 55]. The association between 
BMI and BC risk is thus dependent on the tumor’s ER/PR 
status and the woman’s menopausal status, and in some stud-
ies the risk was modified by hormone replacement therapy 
(HRT) [42, 55, 56].
In addition, HER2 status may be inversely associated with 
BMI, independent of ER status [57], as shown in a study of 
postmenopausal women. Phipps et al. [58], on the other hand, 
found no difference in the association between BMI and 
HER2 status. Additional studies with sufficient numbers of 
HER2-positive and HER2-negative tumors are needed to 
clarify the association between HER2 status and BMI.
Data examining obesity as a risk factor for TNBC are lim-
ited and inconsistent [59, 60]. Case-control studies that evalu-
ated BMI in women irrespective of menopausal status and 
in postmenopausal women found no association with TNBC 
[58, 60–62]. Pooling 2 case-control studies revealed a positive 
association between BMI and TNBC (OR = 2.7; 95% CI = 
1.0–7.5) in postmenopausal women not using HRT [58]. No 
association was observed in HRT users. In a prospective 
study, for postmenopausal women in the highest versus the 
lowest BMI quartile, Phipps et al. [12] observed a 1.35-fold 
(95% CI = 0.92–1.99) non-significantly increased risk of 
TNBC without association with HRT use.
Strength and Limitations
One of the strengths of our study is the comprehensive data 
set prospectively collected from a university breast center 
covering a recent study period (1997–2009). Furthermore, for 
our predictor variable ‘BMI’ we only used directly measured 
BMI data. These are much more reliable than self-reported 
BMI data [63]. Individuals tend to underestimate their weight 
and overestimate their height. BMI was relatively stable over 
the entire study period. It is a distinct finding in the Swiss gen-
eral population that overweight and obesity rates have re-
mained comparatively stable over the last 12 years [18]. Fur-
thermore, we demonstrated that this BMI trend in the general 
population was similar to that in a cohort of BC patients [64].
However, the limitations of our study must also be consid-
ered. The numbers of triple-negative and HER2-positive 
cases were small, reflecting the rarity of these tumor types, 
and this limits the possibilities of drawing meaningful conclu-
sions about the association of BC with BMI for these cases. 
Moreover, HRT use and screening for BC could not be taken 
into account in the present analysis due to lack of adequate 
data in these areas.
Conclusion
In the present study, BMI was a significant factor for tumor 
size at diagnosis; this applied not only to the cases in which 
the tumor was found by self-detection, but also to lesions 
 detected by radiological breast examinations. Even though 
these results strengthen the evidence for a causal relationship 
between BMI and BC outcome, we cannot exclude non- 
adherence to screening for BC as a possible explanation for 
our findings.
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